Evome Medical Technologies Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Evome Medical Technologies Inc. (LNDZF) develops, manufactures, distributes and sells medical devices focused on human performance and rehabilitative solutions in the Americas and internationally; its core products include isokinetic dynamometers such as the SpaceTek Knee Device and System 4 Pro, perturbation gait trainers including the Reactive Step Trainer, balance assessment and recovery devices, neuromuscular electrical and transcutaneous electrical nerve stimulation devices, ultrasound treatment devices, wearable technology for pain management and physical therapy, and related products for prevention, treatment and rehabilitation serving physical therapists, athletic trainers, orthopedic surgeons, hospitals, universities, research centers and healthcare distributors. The company, founded in 2013 and headquartered at 49 Natcon Drive in Shirley, New York, operates through subsidiaries such as Biodex Medical Systems for rehabilitation equipment, Simbex for engineering services, Mio-Guard for custom wearables, Damar Plastics for manufacturing solutions, and South Dakota Partners for supply chain services including assembly, packaging, printing and repair for medical, construction and consumer products sectors. Evome recently changed its name from Salona Global Medical Device Corporation in January 2024 to reflect its innovation focus; launched the Biodex Reactive Step Trainer in December 2023 and SpaceTek Knee Device in November 2023; executed a non-binding letter of intent in February 2024 to extend Simbex acquisition debt to June 2025 while increasing Biodex sales targets by 7.5% and raising product pricing by 2%; announced significant debt reductions and restructurings in February 2025 including 16% less senior secured debt and plans to eliminate acquisition debt via non-core unit sales; appointed Bill Garbarini as Chief Operating Officer and granted him restricted stock units in January 2025; reported Biodex 100% sales growth from January to April 2024 with new distribution deals for U.S. Veterans Health Administration and China markets; launched Evome Medical Products Distribution in 2024 for broader life science portfolio; secured multi-year financing expansions from Pathward including a $3 million facility for Biodex in September 2023; and bolstered its board in February 2024 with executives Wayne Anderson and Bill Garbarini while naming Kenneth Kashkin as Chairman.
Michael Dalsin Resigns as Chairman of the Board of Directors of Evome Medical Technologies
Evome Medical Technologies Provides Market Update
Evome Medical Technologies Appoints Michael Dalsin as Chairman of the Board of Directors; Increases Size of Board to Six
CLARIFICATION: Evome Medical Technologies Announces Significant Debt Restructuring
Evome Medical Technologies Announces Significant Debt Reduction and Restructuring
Evome Medical Technologies Grants Restricted Stock Units to New Chief Operating Officer
Evome Medical Technologies Posts Third Quarter 2024 Results, Generates $424,000 in Adjusted EBITDA on Stable Revenues, Further Reduces Debt
Evome Medical Technologies Announces Results From Its Annual General and Special Meeting of Shareholders
Evome Medical Technologies Reviews Highlights of Low-CapEx Revenue Growth Plan
Evome Medical Technologies Reports Second Quarter 2024 Financial Results
Evome Medical Technologies Retains irlabs for Investor Relations Services
Evome Medical Technologies Announces Update Call with CEO Mike Seckler for Tuesday, June 4, 2024; Provides Update on Strong Q2
Evome Medical Technologies Announces Biodex Generated 100% Sales Growth Comparing April 2024 to January 2024, Plans to Shed Remaining Non-Core Units to Pay Off Remaining Acquisition Debt
Evome Medical Technologies Punctuates Turn Around Plan with Strong Fourth Quarter Resulting in Positive Annual Adjusted EBITDA for Fiscal Year 2023
Evome Medical Engages ICP Securities Inc. for Automated Market Making Services
Evome Medical Technologies Bolsters Board of Directors with Appointment of Strategic Senior Healthcare Executives Wayne Anderson and Bill Garbarini, Appoints Kenneth Kashkin, MD, as Chairman
Salona Global Finalizes Name Change to Evome Medical Technologies to Reflect Turn Around and New Innovation Focus; Restructures Board of Directors
Salona Global Announces Exclusive Partnership with Recently Launched U.S. Military Veteran (VA) Focused Distribution Company
Salona Global Announces the Debut of the Biodex Reactive Step Trainer, a Revolutionary Balance Training System to Reduce Falls; Commences AI Enabled Software Component
Salona Global Announces the Debut of the Biodex SpaceTek Knee™, a Revolutionary Portable Isokinetic Knee Dynamometer Medical Device Developed in NASA Collaboration